Cheryl McAlpine

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock et al. · Clinical Cancer Research · 2020 · 254 citations · Full text

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Sandra P. D’Angelo, Dejka M. Araujo, Albiruni R. Abdul Razak et al. · The Lancet · 2024 · 215 citations · Full text

Afamitresgene Autoleucel, Advanced Synovial Sarcoma, Medicine +3

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

David S. Hong, Brian A. Van Tine, Swethajit Biswas et al. · Nature Medicine · 2023 · 171 citations · Full text

Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.

Mark R. Middleton, Neil Steven, Thomas Evans et al. · Journal of Clinical Oncology · 2016 · 43 citations

Solid Tumor Efficacy, Immunology, Immunoediting +18

Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.

Takami Sato, Paul Nathan, Leonel F. Hernandez‐Aya et al. · Journal of Clinical Oncology · 2017 · 22 citations

Translational Medicine, Imcgp100 Results, Imcgp100 Iv +15